IGHG3 and neoplasm: Non-tumor-specific, antigen-free IgG3 antibodies bind with high affinity to Fcγ receptors, thereby occupying the binding domains of TAMs and NK cells, consequently hindering the interaction with tumor cells as well as ADCC and antibody-mediated phagocytosis (158).